Tvardi Therapeutics
TVRD
134 hedge funds and large institutions have $315M invested in Tvardi Therapeutics in 2018 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 35 reducing their positions, and 31 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 35
0.05% more ownership
Funds ownership: 1.66% → 1.71% (+0.05%)
8% less funds holding
Funds holding: 146 → 134 (-12)
24% less call options, than puts
Call options by funds: $4.34M | Put options by funds: $5.68M
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
44% less capital invested
Capital invested by funds: $563M → $315M (-$248M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$10.8M |
| 2 |
Renaissance Technologies
New York
|
+$7.4M |
| 3 |
First Manhattan
New York
|
+$5.01M |
| 4 |
Citigroup
New York
|
+$3.72M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$17.7M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.11M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.51M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$2.16M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.04M |
TVRD Hedge Fund Activity: Q4 2018 in Review
134 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2018, worth a combined $315M — down 44% from $563M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of TVRD and 23 opened new positions — a net loss of 8 holders — while 35 trimmed existing stakes and 46 added.
The largest buyer was ETF Managers Group, opening a new position worth an estimated $10.8M. The largest seller was Nexthera Capital, exiting entirely with an estimated $17.7M sold.
- 134 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2018, down from 146 in Q3 2018.
- Funds reported $315M of Tvardi Therapeutics stock for Q4 2018, down 44% quarter-over-quarter.
- 23 funds opened new Tvardi Therapeutics positions in Q4 2018 and 31 closed out, a net change of -8 holders.
- The largest Tvardi Therapeutics buyer in Q4 2018 was ETF Managers Group, an estimated $10.8M added.
- The largest Tvardi Therapeutics seller in Q4 2018 was Nexthera Capital, an estimated $17.7M sold.
Based on aggregated 13F filings for Q4 2018.